Navigation Links
InterMune Reports First Quarter 2013 Financial Results and Business Highlights
Date:4/24/2013

cts an estimated 3,500 to 5,000 Canadians.  Approximately one-third of IPF patients in Canada are covered by private insurance and up to six months are needed to secure coverage for new medicines from the major private insurance companies in Canada.  Public (provincial) drug reimbursement plans cover approximately two-thirds of IPF patients in Canada and, on average, about 18 months are needed to secure reimbursement from all 10 provincial governments.
  • On January 9, 2013, enrollment was completed in the confirmatory Phase 3 pirfenidone study, ASCEND, designed to support marketing approval in the United States.  ASCEND is a double-blind, placebo-controlled trial of 52 weeks duration, followed by an approximate five-week safety follow up, with a primary endpoint of change in Forced Vital Capacity (FVC) between baseline and Week 52.  The trial enrolled 555 IPF patients with mild-to-moderate impairment in lung function.  InterMune expects that top-line results from the study will be available in the second quarter of 2014.
  • On February 19, 2013, InterMune reported that the company and Shionogi & Co., Ltd had reached an agreement regarding the material terms of a settlement of the complaint filed by Shionogi against InterMune.  Effective January 1, 2013, InterMune agrees to pay Shionogi a royalty of 4.25% on net sales of Esbriet in the European Union through the remaining period of Orphan Drug exclusivity ending in February 2021.  Shionogi waives any claim against InterMune to royalties on Esbriet sales in Canada or in the United States.
  • On March 4, 2013, InterMune announced that the Pricing Commission (CPR) of the Italian Drug Agency (AIFA) had agreed to pricing and reimbursement conditions for Esbriet.  InterMune anticipates that the launch of Esbriet in Italy will begin following formal approval of the agreement by the Agency Board and publication in the Official Gazette, which is expected in
    '/>"/>

  • SOURCE InterMune, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related biology technology :

    1. InterMune to Report Unaudited Fourth Quarter EsbrietĀ® Revenue and Business Update on January 5
    2. InterMune to Present at J. P. Morgan Healthcare Conference
    3. InterMune to Release Fourth Quarter and Full Year Financial Results on February 9
    4. InterMune To Present At JMP Securities Healthcare Conference
    5. InterMune To Release Third Quarter Financial Results On November 7
    6. InterMune Reports Third Quarter 2012 Financial Results And Business Highlights
    7. InterMune Reports Fourth Quarter And Full Year 2012 Financial Results And Business Highlights
    8. InterMune To Release First Quarter Financial Results On April 24
    9. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
    10. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
    11. Interleukin Genetics Reports Third Quarter 2011 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:11/26/2014)... Texas (PRWEB) November 26, 2014 ... Industry is an in-depth research report on the ... the report introduces Palmitic Acid, basic information, including ... policy analysis, and news analysis, etc. , ... analyzes Palmitic Acid market in China ...
    (Date:11/24/2014)... Nov. 24, 2014  IGI Laboratories, Inc. (NYSE MKT: ... specialty generic pharmaceutical company, today announced it has submitted ... U.S. Food and Drug Administration (FDA), which brings the ... seven, with eighteen submissions now pending at the FDA. ... CEO of the Company, commented, "Our team here at ...
    (Date:11/24/2014)... , Nov. 24, 2014   Veracyte, Inc. ... H. Anderson , president and chief executive officer, will present ... th Annual Healthcare Conference on Tuesday, December 2, 2014 ... . The live audio webcast and subsequent replay ... . Please connect to the website at least 15 minutes ...
    (Date:11/24/2014)... , Nov. 24, 2014  Spherix Incorporated ... company committed to the fostering and monetization of ... v. VTech Telecommunications Ltd.,  Case No. 3:13-cv-03494-M and  ... No. 3:13-cv-03496-M, both in the United States District ... Texas . On November ...
    Breaking Biology Technology:Palmitic Acid Industry Global 2014 Analysis & 2020 Forecasts on Market data, Statics, Development Now at ReportsnReports.com 2Palmitic Acid Industry Global 2014 Analysis & 2020 Forecasts on Market data, Statics, Development Now at ReportsnReports.com 3IGI Laboratories, Inc. Announces ANDA Submission 2Veracyte to Present at the Piper Jaffray 26th Annual Healthcare Conference 2Markman Hearing Held as Scheduled in VTech and Uniden Cases 2
    ... Data , , THOUSAND OAKS, Calif., June 22 ... that the U.S. Food and Drug Administration (FDA) has asked ... Health Drugs Advisory Committee (RHDAC) on Aug. 13, 2009. The ... for denosumab, a RANK Ligand inhibitor for which Amgen is ...
    ... Pharmaceutical Research and Manufacturers of America ... statement regarding today,s AARP-White House press conference on health care ... we believe this agreement will be looked back in time ... our troubled health care system. Our $80 billion pledge ...
    ... COLUMBUS, Ohio, June 22 Mettler-Toledo International Inc. (NYSE: ... has been appointed to its Board of Directors, effective July ... and Chief Executive Officer of Millipore Corporation (NYSE: ... research and biopharmaceutical manufacturing industry. Prior to joining Millipore ...
    Cached Biology Technology:Amgen to Participate in Reproductive Health Drugs Advisory Committee Meeting in August 2Amgen to Participate in Reproductive Health Drugs Advisory Committee Meeting in August 3Amgen to Participate in Reproductive Health Drugs Advisory Committee Meeting in August 4Amgen to Participate in Reproductive Health Drugs Advisory Committee Meeting in August 5Amgen to Participate in Reproductive Health Drugs Advisory Committee Meeting in August 6Amgen to Participate in Reproductive Health Drugs Advisory Committee Meeting in August 7PhRMA Statement on AARP-White House Press Conference 2Martin Madaus Joins Mettler Toledo Board of Directors 2
    (Date:11/10/2014)... on U.S. store shelves in early 2010, and people ... small packets can be tossed into a washing machine ... powder. The convenience, though, has come with risks for ... Nationwide Children,s Hospital found that from 2012 through 2013, ... younger than 6 years of age swallowing, inhaling, or ...
    (Date:11/6/2014)... paper from a team of Florida State University biologists ... could adapt to and survive environmental swings such as ... latest issue of the journal The Plant Cell ... DNA and proteins) is organized in a cell and ... are turned on and others are turned off. , ...
    (Date:11/5/2014)... Santamaria, associate professor of biology in the UTSA ... in the nation selected to receive a two-year ... for Exploratory Research (EAGER). The funding supports President ... researchers to create new technology that will demystify ... complex behaviors in neuroscience are broken into the ...
    Breaking Biology News(10 mins):Study finds laundry detergent pods, serious poisoning risk for children 2Maize analysis yields whole new world of genetic science 2UTSA biology professor awarded $300,000 NSF grant for brain research 2UTSA biology professor awarded $300,000 NSF grant for brain research 3
    ... published an overview of sales of various drugs used ... are shown in kilograms of active ingredient; antibacterials, anaesthetics, ... figures are based on sales from wholesalers to pharmacies ... an increase in sales of antibacterials from 2002-2006, sales ...
    ... the School of Biological Sciences at Queens University, found the ... University College Cork and BirdWatch Ireland. Its natural range is ... the closest it has been spotted to Ireland is in ... was studying the diet of the Barn Owl in Ireland. ...
    ... emerged as an important signaling molecule in plants - ... tropical medicinal herb as a model plant, researchers have ... and enzymes in plants. In collaborative work with ... and her doctoral student at the Botany Department, University ...
    Cached Biology News:For good or ill Ireland gains another mammal species 2Nitric oxide regulates plants as well as people 2
    MHC. Sections include: the isolation and functional properties of antigen-presenting cells analysis of MHC class II endocytosis and peptide turnover analysis of signalling via MHC class II molecu...
    Supplemental reagent for annexin V assay....
    Large-fragment, single-stranded carrier DNA of the highest quality, perfectly suited for all types of yeast transformation....
    Qa-1 (L-12)...
    Biology Products: